Coming out of one of the bellwether events for the healthcare industry, attorneys in the space are feeling pretty good about 2026. Julie Tibbets, chair of the Life Sciences Regulatory and Compliance practice at Goodwin, told Law360 Healthcare Authority it feels like there may be a "reset" happening at the U.S. Food and Drug Administration. "There's hope that we'll see fewer complete response letters, more first approvals the first time through," Tibbets said. "There's some stabilization that we're finally starting to see," she added. "And everybody at the conference, everybody's very hopeful." Heath Ingram, a partner at Goodwin, is watching to see how so-called most favored nation pricing policies affect the industry in 2026. MFN is the Trump administration's attempt to bring prescription drug prices in the US in line with those in other developed countries. So far, the White House has struck individual deals with pharmaceutical companies to bring prices down for certain drugs. In late December, the administration also announced two mandatory Center for Medicare and Medicaid Innovation models that propose MFN-based rebates in Medicare Parts B and D. "Those proposed rules were released shortly before the Christmas holiday, and manufacturers have been trying to make sense of them since," Ingram said. "At a high level, manufacturers are very concerned about what an MFN final rule would look like ... and they're trying to figure out how do they respond."